| Sheryl Catherine Rife, CNM | |
|
921 Jasonway Ave Ste B, Columbus, OH 43214-2456 | |
| (614) 916-9730 | |
| (614) 447-8876 |
| Full Name | Sheryl Catherine Rife |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 921 Jasonway Ave Ste B, Columbus, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093188922 | NPI | - | NPPES |
| 0150192 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | RN360473 (Ohio) | Secondary |
| 367A00000X | Advanced Practice Midwife | APRN.CNM.18382 (Ohio) | Primary |
| Entity Name | Professionals For Womens Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649384223 PECOS PAC ID: 0749259919 Enrollment ID: O20040927000053 |
News Archive
In a new paper published in the The Lancet Regional Health - Europe, Mr Gabriele Guaitoli and Dr Roberto Pancrazi from the Department of Economics at Warwick University investigate whether region-wide non-pharmaceutical interventions introduced in Italy during the second wave of Covid-19 in Fall 2020 have been effective at eliminating local risk factors.
Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced the launch of Colvera, a blood-based test for colorectal cancer (CRC) recurrence monitoring. Colvera is the result of a decade of research, development and clinical validation in more than 4,000 patients.
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has secured an initial funding round of $2.5 million from four investors – three biotechnology venture capital groups and one angel investor. The round will finance a clinical trial and laboratory testing of a new, minimally invasive blood test designed to identify risks to pregnancy ranging from pre-term birth to genetic conditions.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sheryl Catherine Rife, CNM 921 Jasonway Ave Ste B, Columbus, OH 43214-2456 Ph: (614) 268-8800 | Sheryl Catherine Rife, CNM 921 Jasonway Ave Ste B, Columbus, OH 43214-2456 Ph: (614) 916-9730 |
News Archive
In a new paper published in the The Lancet Regional Health - Europe, Mr Gabriele Guaitoli and Dr Roberto Pancrazi from the Department of Economics at Warwick University investigate whether region-wide non-pharmaceutical interventions introduced in Italy during the second wave of Covid-19 in Fall 2020 have been effective at eliminating local risk factors.
Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced the launch of Colvera, a blood-based test for colorectal cancer (CRC) recurrence monitoring. Colvera is the result of a decade of research, development and clinical validation in more than 4,000 patients.
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has secured an initial funding round of $2.5 million from four investors – three biotechnology venture capital groups and one angel investor. The round will finance a clinical trial and laboratory testing of a new, minimally invasive blood test designed to identify risks to pregnancy ranging from pre-term birth to genetic conditions.
› Verified 2 days ago
Kathleen Elizabeth Waibel, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 921 Jasonway Ave Ste B, Columbus, OH 43214 Phone: 614-268-8800 Fax: 614-447-8876 | |
Kortney Fisher, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 882 S Hamilton Rd, Columbus, OH 43213 Phone: 614-235-5555 | |
Mallory B Kahrs, APRN-CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1581 Dodd Dr Fl 4, Columbus, OH 43210 Phone: 614-293-3069 Fax: 614-293-4780 | |
Elizabeth Christy, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 921b Jasonway Ave, Columbus, OH 43214 Phone: 614-268-8800 Fax: 614-268-8249 | |
Lindsay R Eckman, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 3555 Olentangy River Rd Ste 4050, Columbus, OH 43214 Phone: 614-566-2727 Fax: 614-566-2712 | |
Mary Ann Chambers, BSN Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 240 Parsons Ave, Columbus, OH 43215 Phone: 614-645-1850 |